Literature DB >> 21986524

High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis.

Jiyun Ahn1, Hyunjung Lee, Chang Hwa Chung, Taeyoul Ha.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic fat accumulation and is presently the most common chronic liver disease. However, the mechanisms underlying the development of steatosis remain unclear. MicroRNAs (miRNAs) are small non-coding RNAs that modulate a variety of biological functions. We have investigated the role of miRNA in the development of steatosis. We found that miR-467b expression is significantly downregulated in liver tissues of high-fat diet fed mice and in steatosis-induced hepatocytes. The downregulation of miR-467b resulted in the upregulation of hepatic lipoprotein lipase (LPL), the direct target of miR-467b. Moreover, the interaction between miR-467b and LPL was associated with insulin resistance, a major cause of NAFLD. These results suggest that downregulation of miR-467b is involved in the development of hepatic steatosis by modulating the expression of its target, LPL.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986524     DOI: 10.1016/j.bbrc.2011.09.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

Review 1.  Micro RNAs in the development of non-alcoholic fatty liver disease.

Authors:  Glenn S Gerhard; Johanna K DiStefano
Journal:  World J Hepatol       Date:  2015-02-27

2.  Combinatorial regulation of lipoprotein lipase by microRNAs during mouse adipogenesis.

Authors:  Maria Bouvy-Liivrand; Merja Heinäniemi; Elisabeth John; Jochen G Schneider; Thomas Sauter; Lasse Sinkkonen
Journal:  RNA Biol       Date:  2014-01-16       Impact factor: 4.652

3.  High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.

Authors:  Fatjon Leti; Ivana Malenica; Meera Doshi; Amanda Courtright; Kendall Van Keuren-Jensen; Christophe Legendre; Christopher D Still; Glenn S Gerhard; Johanna K DiStefano
Journal:  Transl Res       Date:  2015-05-04       Impact factor: 7.012

4.  MicroRNA 375 mediates palmitate-induced enteric neuronal damage and high-fat diet-induced delayed intestinal transit in mice.

Authors:  Behtash Ghazi Nezami; Simon M Mwangi; Jai Eun Lee; Sabrina Jeppsson; Mallappa Anitha; Shadi S Yarandi; Alton B Farris; Shanthi Srinivasan
Journal:  Gastroenterology       Date:  2013-10-25       Impact factor: 22.682

Review 5.  Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives.

Authors:  Ravi Kasiappan; Dheeran Rajarajan
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

Review 6.  miRNAs in non-alcoholic fatty liver disease.

Authors:  Zhen He; Cheng Hu; Weiping Jia
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

7.  Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system.

Authors:  Jacqueline R Kemp; Hamiyet Unal; Russell Desnoyer; Hong Yue; Anushree Bhatnagar; Sadashiva S Karnik
Journal:  J Mol Cell Cardiol       Date:  2014-06-27       Impact factor: 5.000

Review 8.  Effect of Dietary Fatty Acids on MicroRNA Expression Related to Metabolic Disorders and Inflammation in Human and Animal Trials.

Authors:  Karla MacDonald-Ramos; Alejandra Martínez-Ibarra; Adriana Monroy; Juan Miranda-Ríos; Marco Cerbón
Journal:  Nutrients       Date:  2021-05-27       Impact factor: 5.717

9.  Increased serum levels of lipogenic enzymes in patients with severe liver steatosis.

Authors:  Maria Notarnicola; Giovanni Misciagna; Valeria Tutino; Marisa Chiloiro; Alberto Ruben Osella; Vito Guerra; Caterina Bonfiglio; Maria Gabriella Caruso
Journal:  Lipids Health Dis       Date:  2012-10-30       Impact factor: 3.876

Review 10.  Dual role of microRNAs in NAFLD.

Authors:  Sara Ceccarelli; Nadia Panera; Daniela Gnani; Valerio Nobili
Journal:  Int J Mol Sci       Date:  2013-04-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.